Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Reich

Showing results (101-110 of 218) with videos related to

Pageof 22
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|January 22, 2021
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion methodU Mrowietz, R B Warren, C L Leonardi, et al.
Genes and Immunity|May 16, 2008
Association analysis of IL20RA and IL20RB genes in psoriasisK Kingo, R Mössner, R Rätsep, et al.
Dermatology (Basel, Switzerland)|March 10, 2009
Health services research in psoriasis--the German approachM Augustin, K Reich, M Reusch, et al.
The Journal of Experimental Medicine|January 1, 1992
Oligoclonality of human intestinal intraepithelial T cellsC Van Kerckhove, G J Russell, K Deusch, et al.
Archives of Oral Biology|June 30, 2009
Periodontal histomorphometry and status of aged sheep subjected to ovariectomy, malnutrition and glucocorticoid applicationG Dvorak, K Reich, S Tangl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 26, 2020
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trialR B Warren, J M Carrascosa, E Fumero, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2018
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trialsA Blauvelt, K Reich, M Lebwohl, et al.
Clinical and Experimental Dermatology|January 4, 2017
Psoriasis and metabolic syndrome in children: current dataA Pietrzak, E Grywalska, M Walankiewicz, et al.
The British Journal of Dermatology|September 6, 2019
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studiesA B Kimball, K A Papp, K Reich, et al.
The British Journal of Dermatology|June 28, 2003
Cytokine gene polymorphisms in atopic dermatitisK Reich, G Westphal, I R König, et al.
Pageof 22

Showing results (101-110 of 218) with videos related to

Sort By:
Pageof 22
Journal of the European Academy of Dermatology and Venereology : JEADV|January 22, 2021
Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion methodU Mrowietz, R B Warren, C L Leonardi, et al.
Genes and Immunity|May 16, 2008
Association analysis of IL20RA and IL20RB genes in psoriasisK Kingo, R Mössner, R Rätsep, et al.
Dermatology (Basel, Switzerland)|March 10, 2009
Health services research in psoriasis--the German approachM Augustin, K Reich, M Reusch, et al.
The Journal of Experimental Medicine|January 1, 1992
Oligoclonality of human intestinal intraepithelial T cellsC Van Kerckhove, G J Russell, K Deusch, et al.
Archives of Oral Biology|June 30, 2009
Periodontal histomorphometry and status of aged sheep subjected to ovariectomy, malnutrition and glucocorticoid applicationG Dvorak, K Reich, S Tangl, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 26, 2020
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trialR B Warren, J M Carrascosa, E Fumero, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 23, 2018
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trialsA Blauvelt, K Reich, M Lebwohl, et al.
Clinical and Experimental Dermatology|January 4, 2017
Psoriasis and metabolic syndrome in children: current dataA Pietrzak, E Grywalska, M Walankiewicz, et al.
The British Journal of Dermatology|September 6, 2019
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studiesA B Kimball, K A Papp, K Reich, et al.
The British Journal of Dermatology|June 28, 2003
Cytokine gene polymorphisms in atopic dermatitisK Reich, G Westphal, I R König, et al.
Pageof 22